Apexigen, Inc is a biotechnology company based in San Carlos, CA, specializing in the development of therapeutics for difficult-to-treat cancers. With a focus on antibody-drug conjugates (ADCs) and immunotherapies, their differentiated portfolio of clinical assets aims to deliver potent cancer-killing agents directly to tumor cells and mobilize the body's immune system to attack cancer cells. Through their innovative technology platform, Apexigen is dedicated to developing safer and more effective treatments to improve outcomes and enhance the quality of life for cancer patients.
Pyxis Oncology, a subsidiary of Apexigen, is committed to charting a course in the field of oncology by developing next-generation therapeutics. Their broad pipeline includes novel ADC and monoclonal antibody (mAb) product candidates, which are being developed as monotherapies and in combination with other therapies. By prioritizing lead ADC programs and focusing on targeting difficult-to-treat cancers, Pyxis Oncology aims to make significant advancements in the fight against cancer and provide hope for patients in need.
Generated from the website